NYSE$CRL

Charles River Laboratories International Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Charles River Labs' Q4 2023 results were announced, featuring a revenue decrease and earnings per share of $3.62.

Charles River Laboratories reported a Q4 2023 revenue of $1.01 billion, a 7.9% decrease compared to Q4 2022. GAAP earnings per share were $3.62, while non-GAAP earnings per share were $2.46. The company's performance reflected moderating demand trends in the life sciences sector.

  • Q4 revenue was $1.01 billion, a decrease of 7.9% year-over-year.
  • GAAP earnings per share were $3.62, a decrease of 0.8% year-over-year.
  • Non-GAAP earnings per share were $2.46, a decrease of 17.4% year-over-year.
  • GAAP operating margin decreased to 13.1% from 14.9% in the fourth quarter of 2022.

Headline financials

Total Revenue

$1.01B

Previous: $1.1B-7.9%
EPS (adj)

$2.46

Previous: $2.98-17.4%
Capital Expenditures

-$78.3M

No prior period
Net Income

$189M

Previous: $189M-0.1%
Operating Income

$133M

Previous: $164M-18.9%
Gross Profit

$364M

Previous: $399M-8.7%
Stock-Based Comp

$19.5M

Previous: $22.1M-11.5%

Revenue & EPS history

Charles River Labs · Revenue · Quarterly

$1.01B

Q4 2023-7.9%vs Q4 2022
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Charles River Labs · $1.03B total across 3 segments · Q3 2023

  • Discovery & Safety Assessment
    $664M+7.2%
  • Research Models & Services
    $187M+3.7%
  • Manufacturing Solutions
    $176M-7.3%

Forward guidance

The company is providing financial guidance for 2024. The 2024 revenue growth outlook reflects a continuation of the more cautious biopharmaceutical demand environment that the Company experienced throughout most of 2023.

Tailwinds

  • Revenue growth, reported 1.0% – 4.0%
  • Impact of divestitures/(acquisitions), net ~(0.5)%
  • (Favorable)/unfavorable impact of foreign exchange ~(0.5)%
  • Revenue growth, organic (1) 0.0% – 3.0%
  • Non-GAAP EPS estimate $10.90 – $11.40

Headwinds

  • Acquisition-related amortization (2) ~$2.40
  • Acquisition and integration-related adjustments (3) ~$0.10
  • Costs associated with restructuring actions (4) ~$0.25
  • Other items (5) ~$0.25
  • The 2024 revenue growth outlook reflects a continuation of the more cautious biopharmaceutical demand environment that the Company experienced throughout most of 2023.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+0.1%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+0.7%

Avg return

30 days after

47%

32 / 68 earnings

Positive

+18.4%

Q1 2025

Best reaction

-13.3%

Q3 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.8%-9.0%-0.1%
Q4 2025-1.8%+3.1%-3.1%
Q3 2025-5.5%-5.0%+3.6%
Q1 2025+18.4%+24.0%+25.4%
Q4 2024+6.9%+10.4%+8.3%
Q3 2024+11.5%+17.0%+1.7%
Q2 2024-11.7%-15.1%-17.8%
Q1 2024-3.0%-1.0%-8.7%
Q4 2023+11.4%+11.2%+17.6%
Q3 2023-7.3%-7.0%+11.8%
Q2 2023+5.5%+5.2%-3.2%
Q1 2023+2.7%+1.0%+6.1%
Q4 2022-6.7%-9.0%-20.4%
Q3 2022+4.8%+9.0%+7.4%
Q2 2022-6.6%-9.4%-17.8%
Q1 2022-1.2%-8.9%-3.3%
Q4 2021-6.7%-6.1%-8.3%
Q3 2021-12.2%-13.4%-17.3%
Q2 2021-0.3%-0.4%+9.3%
Q1 2021+4.0%+3.2%-0.1%
Q4 2020+2.0%-1.1%-0.0%
Q3 2020+2.6%+7.0%+3.7%
Q2 2020+6.8%+7.3%+0.4%
Q1 2020+11.1%+12.0%+24.2%
Q4 2019+8.6%+11.9%-21.3%
Q3 2019-2.5%+1.1%+12.0%
Q2 2019-5.1%-10.3%-7.0%
Q1 2019-4.2%-4.1%-10.4%
Q4 2018+8.1%+9.0%+11.1%
Q3 2018+8.8%+6.8%+3.0%
Q2 2018-5.2%-6.6%-1.6%
Q1 2018+0.3%-1.0%+8.5%
Q4 2017+8.2%+6.0%+9.9%
Q3 2017-13.3%-14.3%-11.9%
Q2 2017-1.7%-0.2%+10.0%
Q1 2017-3.8%-2.3%+2.8%
Q4 2016+7.6%+7.3%+8.4%
Q3 2016-9.0%-5.1%-3.0%
Q2 2016-0.0%-3.1%-3.0%
Q1 2016+2.5%
Q4 2015+3.9%
Q3 2015+5.7%
Q2 2015+1.4%
Q1 2015-8.8%
Q4 2014+6.3%
Q3 2014-1.9%
Q2 2014+6.0%
Q1 2014-6.6%
Q4 2013-1.6%
Q3 2013-1.2%
Q2 2013+3.4%
Q1 2013-3.9%
Q4 2012+0.9%
Q3 2012-5.3%
Q2 2012+2.3%
Q1 2012+1.8%
Q4 2010-1.3%
Q4 2011-1.3%
Q3 2011-5.0%
Q2 2011-9.4%
Q1 2010-2.4%
Q1 2011-0.1%
Q4 2008-0.9%
Q3 2010-4.4%
Q3 2009-4.4%
Q2 2010+3.6%
Q4 2009+3.6%
Q2 2009+3.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro